A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Durvalumab and Bacillus Calmette-Guérin (BCG) vs BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients (POTOMAC)

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com